Sientra (NASDAQ:SIEN) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Thursday.
Several other equities analysts have also commented on the stock. Canaccord Genuity restated a “buy” rating and issued a $14.00 price objective on shares of Sientra in a report on Sunday, October 8th. Stifel Nicolaus restated a “hold” rating and issued a $14.00 price objective (up from $11.00) on shares of Sientra in a report on Wednesday, September 27th. William Blair upgraded shares of Sientra from a “market perform” rating to an “outperform” rating in a report on Wednesday, September 13th. Finally, Zacks Investment Research lowered shares of Sientra from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $13.75.
Sientra (SIEN) traded up $0.03 during trading hours on Thursday, reaching $12.97. 119,911 shares of the company’s stock traded hands, compared to its average volume of 152,400. The company has a current ratio of 2.87, a quick ratio of 1.92 and a debt-to-equity ratio of 0.57. Sientra has a 12 month low of $7.20 and a 12 month high of $16.68.
Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new position in shares of Sientra in the 2nd quarter worth approximately $101,000. Nationwide Fund Advisors lifted its holdings in Sientra by 260.4% during the 2nd quarter. Nationwide Fund Advisors now owns 10,963 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 7,921 shares in the last quarter. Accredited Investors Inc. acquired a new stake in Sientra during the 2nd quarter worth approximately $115,000. New York State Common Retirement Fund acquired a new stake in Sientra during the 2nd quarter worth approximately $148,000. Finally, Rhumbline Advisers acquired a new stake in Sientra during the 2nd quarter worth approximately $158,000. Hedge funds and other institutional investors own 76.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Sientra (SIEN) Rating Lowered to Sell at BidaskClub” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/07/sientra-sien-rating-lowered-to-sell-at-bidaskclub.html.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc and related companies with MarketBeat.com's FREE daily email newsletter.